Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations. 

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is pulling together philanthropic, non-profit and private sector participants to collaboratively run Phase II trials for five drugs from Janssen, Otsuka, the TB Alliance and the Bill & Melinda Gates Medical Research Institute.

Brexpiprazole could be approved as soon as 2023, and Lundbeck has pledged to support its uptake with investment in its salesforce and direct-to-consumer advertising.

Following an investigator-initiated clinical development program demonstrating its value, Japan has granted reimbursement to UCB's anticonvulsant E Keppra for status epilepticus, pending what appears to be the formal approval globally in this indication.